ATOS Atossa Genetics Inc

USD 1.48 0.14 10.447761
Icon

Atossa Genetics Inc (ATOS) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 1.48

+0.14 (+10.45)%

USD 0.19B

1.22M

USD 5.04(+240.65%)

USD 2.78 (+87.84%)

Icon

ATOS

Atossa Genetics Inc (USD)
COMMON STOCK | NSD
USD 1.48
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.19B

USD 2.78 (+87.84%)

USD 1.48

Atossa Genetics Inc (ATOS) Stock Forecast

Show ratings and price targets of :
USD 5.04
(+240.65%)

Based on the Atossa Genetics Inc stock forecast from 2 analysts, the average analyst target price for Atossa Genetics Inc is USD 5.04 over the next 12 months. Atossa Genetics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Atossa Genetics Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Atossa Genetics Inc’s stock price was USD 1.48. Atossa Genetics Inc’s stock price has changed by +5.71% over the past week, +30.97% over the past month and +30.97% over the last year.

No recent analyst target price found for Atossa Genetics Inc
No recent average analyst rating found for Atossa Genetics Inc

Company Overview Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolit...Read More

107 Spring Street, Seattle, WA, United States, 98104

12

December

USD

USA

Adjusted Closing Price for Atossa Genetics Inc (ATOS)

Loading...

Unadjusted Closing Price for Atossa Genetics Inc (ATOS)

Loading...

Share Trading Volume for Atossa Genetics Inc Shares

Loading...

Compare Performance of Atossa Genetics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ATOS

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Atossa Genetics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing ATOS

Symbol Name ATOS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Atossa Genetics Inc (ATOS) Stock

Based on ratings from 2 analysts Atossa Genetics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 6 buy, sell and hold ratings.

Unfortunately we do not have enough data on ATOS's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for ATOS is USD 5.04 over the next 12 months. The maximum analyst target price is USD 6.25 while the minimum anlayst target price is USD 4.

Unfortunately we do not have enough data on ATOS's stock to indicate if its overvalued.

The last closing price of ATOS's stock was USD 1.48.

The most recent market capitalization for ATOS is USD 0.19B.

Based on targets from 2 analysts, the average taret price for ATOS is projected at USD 5.04 over the next 12 months. This means that ATOS's stock price may go up by +240.65% over the next 12 months.

We can't find any ETFs which contains Atossa Genetics Inc's stock.

As per our most recent records Atossa Genetics Inc has 12 Employees.

Atossa Genetics Inc's registered address is 107 Spring Street, Seattle, WA, United States, 98104. You can get more information about it from Atossa Genetics Inc's website at https://atossatherapeutics.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...